| Literature DB >> 35843720 |
Charly Phillips1, Brennan Chapman1,2, Agnes Agunos3, Carolee A Carson3, E Jane Parmley2, Richard J Reid-Smith2,3, Ben A Smith1, Colleen P Murphy3.
Abstract
Antimicrobial resistance (AMR) is a complex problem that is a threat to global public health. Consumption of turkey meat may be an important source of foodborne exposure to resistant bacteria; recent outbreaks of multi-drug-resistant Salmonella Reading in Canada and the USA have implicated raw turkey products. To better understand the epidemiology of AMR in farmed turkey production, a scoping review was conducted. The objectives were to identify (1) modifiable factors potentially associated with antimicrobial-resistant Campylobacter, Enterococcus, Escherichia coli and Salmonella enterica along the farm-to-fork pathway in turkeys, and (2) data gaps with respect to factors potentially associated with AMR and Canadian commercial turkey production. A comprehensive search of the peer-reviewed literature was conducted in 2019 and updated in 2021. Thirteen references were included, reporting 36 factors. Antimicrobial use factors and their potential associations with AMR were most frequently reported (n = 15 factors; 42%), followed by biosecurity (n = 11; 31%) and management practices (n = 10; 28%). This review revealed important data gaps; no factors pertaining to S. enterica or to stages other than the farm (e.g. abattoir, retail) were identified, and only one Canadian reference was identified. These findings will inform priorities for future research and surveillance regarding turkeys and AMR.Entities:
Keywords: Antibiotic resistance; Canada; antimicrobial resistance in agricultural settings; foodborne infections; turkeys
Mesh:
Substances:
Year: 2022 PMID: 35843720 PMCID: PMC9428905 DOI: 10.1017/S0950268822001224
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 4.434
Fig. 1.Flowchart depicting the criteria used to guide reviewer decisions at primary (title/abstract) screening. aCitations were excluded if the year of sampling was the only factor reported, as year was deemed a non-modifiable factor. However, if the abstract indicated that samples were taken over a time period greater than or equal to 10 years (and the citation passed all previous primary screening questions in this flowchart), the citation was included, as this time period was potentially extensive enough to include samples taken before and after AMU policy changes, which are modifiable factors. If such policy changes were described in the full text (at secondary screening), the reference was potentially eligible for inclusion at secondary screening.
Fig. 2.Flowchart depicting the criteria used to guide reviewer decisions at secondary (full-text) screening. Y, yes; N, no. Exclusion decisions displayed here were sometimes made at the data extraction stage, rather than at secondary screening, as the applicability of these reasons to particular references were more obvious in some cases than in others. All shapes with dotted lines represent those exclusion decisions that more often required the extra scrutiny applied at the data extraction stage, while shapes with solid lines represent exclusion decisions that were made at the secondary screening stage. aThis includes references reporting a potential association between a factor and the occurrence of an AMR gene, as long as the potential association was reported in a specified, relevant bacterial species.
Fig. 3.PRISMA flow diagram of citations and references through the scoping review process to identify factors potentially associated with AMR in Campylobacter species, Enterococcus species, E. coli and S. enterica from turkeys. Counts at each step in the flow diagram reflect the totals for the initial and updated searches combined. aThese include: (1) duplicates within the returns of each search, and (2) duplicates that emerged when the results of the updated search were de-duplicated against the results of the initial search. bA detailed description of the exclusion criteria at primary (title/abstract) screening is available in Figure 1. cErrata were not counted as individual references starting at full-text screening, as they were paired with their corresponding full-text articles. dA detailed description of the exclusion criteria at secondary (full-text) screening is available in Figure 2. eTurkey references: references which reported sampling turkey-origin bacteria in the full text.
Description of factors (AMU: AMU policy change and binary qualitative AMU themes) potentially associated with AMR in Campylobacter species, Enterococcus species and E. coli from turkeys
| Population | Study design | Factor group | Comparator group | Bacteria | Resistance outcome | Location | Reference |
|---|---|---|---|---|---|---|---|
| Commercial turkeys | Observational | After French Act No. 2014-1170 went into effect, which imposed incentive tools to reduce the use of critically important antimicrobials | Before French Act No. 2014-1170 went into effect (sampling from 2014) | Ciprofloxacin | France | [ | |
| Erythromycin | |||||||
| Gentamicin | |||||||
| Ciprofloxacin | |||||||
| Nalidixic acid | |||||||
| After both Decree 2016-317, which banned the preventive use of critically important antimicrobials | Before the passage of either French Act No. 2014-1170 or Decree 2016-317 (sampling from 2014) | Ciprofloxacin | |||||
| Erythromycin | |||||||
| Gentamicin | |||||||
| Ciprofloxacin | |||||||
| Nalidixic acid | |||||||
| Ceftiofur use (in hatchery) | No ceftiofur use (in hatchery) | Ceftiofur | Canada | [ | |||
| Enrofloxacin use in the last year | No enrofloxacin use in the last year | Ciprofloxacin | USA | [ | |||
| Gentamicin use (in hatchery) | No gentamicin use (in hatchery) | Gentamicin | Canada | [ | |||
| Tylosin use (preventive in-feed) | No tylosin use (preventive in-feed) | Tylosin | |||||
| Virginiamycin use (preventive in-feed) | No virginiamycin use (preventive in-feed) | Quinupristin and dalfopristin | |||||
| Virginiamycin use in the last year | No virginiamycin use in the last year | Quinupristin and dalfopristin | USA | [ | |||
| Bacitracin use (preventive in-feed) | No bacitracin use (preventive in-feed) | Bacitracin | Canada | [ | |||
| Tetracycline use (preventive in-feed or as treatment) | No tetracycline use (preventive in-feed or as treatment) | Tetracycline | |||||
| Any antimicrobial treatment administered to the flock | No antimicrobial treatment administered to the flock | Ciprofloxacin | Great Britain | [ | |||
| Any subtherapeutic AMU (in-feed) | No in-feed AMU for the last 3 or more years | Gentamicin | USA | [ | |||
| Neomycin | |||||||
| Sulphathiazole and trimethoprim | |||||||
| Clindamycin | |||||||
| Erythromycin | |||||||
| Tilmicosin | |||||||
| Ampicillin | |||||||
| Penicillin | |||||||
| Spectinomycin | |||||||
| Florfenicol | |||||||
| Sulphadimethoxine | |||||||
| Chlortetracycline | |||||||
| Oxytetracycline | |||||||
| Tiamulin | |||||||
| Subtherapeutic AMU (in-feed) | No AMU via feed or water | Gentamicin | USA | [ | |||
| Breeder turkeys | Observational | Fluoroquinolone treatment in the last year | No fluoroquinolone treatment in the last year | Ciprofloxacin | Great Britain | [ |
Factor group: the study group in which the factor was present or applied (e.g. a group of turkeys in which chlortetracycline was administered in-feed).
Comparator group: the study group in which the factor was not present or applied (e.g. a group of turkeys in which chlortetracycline was not administered in-feed).
As designated by the World Health Organization [23].
Birds in both the factor and comparator groups were administered antimicrobials in ovo and as poults (eggs were dipped into a solution of tylosin (300 μl/ml) and gentamicin (500 ppm), and poults received 1 mg of gentamicin via injection after hatching) [41].
Description of the factors (AMU: binary quantitative AMU theme) potentially associated with AMR in Campylobacter species, Enterococcus species and E. coli from turkeys
| Population | Study design | Factor group | Comparator group | Bacteria | Resistance outcome | Location | Reference |
|---|---|---|---|---|---|---|---|
| Commercial turkeys | Observational | Neo-terramycin use (oxytetracycline hydrochloride at 106 mg/l and neomycin sulphate at 74 mg/l of H2O) for 3 days | No AMU via feed or water | Gentamicin | USA | [ | |
| Chlortetracycline use (106 mg/l H2O) for 9 h | No AMU via feed or water | ||||||
| Chlortetracycline use (106 mg/l H2O) for 3 days | No AMU via feed or water | ||||||
| Chlortetracycline use (106 mg/l H2O) for 4 days | No AMU via feed or water | ||||||
| Continuous chlortetracycline use (200 mg/kg), administered in-feed | No AMU via feed or water | ||||||
| Nitrofurazone use (220 mg/kg) for 1 week, administered in-feed | No AMU via feed or water | ||||||
| Nitrofurazone use (220 mg/kg) for 1 week and continuous chlortetracycline use (220 mg/kg), both administered in-feed | No AMU via feed or water | ||||||
| Non-observational | Enrofloxacin use (10 mg enrofloxacin/kg body weight per day, via drinking water) for 5 days | No enrofloxacin use | Enrofloxacin | USA | [ | ||
| Ampicillin | |||||||
| Pulsed tylosin use (60 mg tylosin/kg body weight, via a therapeutic dose of 0.53 g/l H2O) in 3 separate dosing periods lasting 3 days each | No AMU (in water) | Erythromycin | USA | [ | |||
| Breeder turkeys | Non-observational | Paromomycin sulphate use (100 mg/kg), administered in-feed from day of hatch to day 120 | No paromomycin use | Teicoplanin | France | [ | |
| Vancomycin | |||||||
| Gentamicin | |||||||
| Kanamycin | |||||||
| Streptomycin | |||||||
| Sulphamethoxazole and trimethoprim | |||||||
| Lincomycin | |||||||
| Erythromycin | |||||||
| Ampicillin | |||||||
| Pristinamycin | |||||||
| Chloramphenicol | |||||||
| Tetracycline | |||||||
| Ciprofloxacin | |||||||
| Amikacin | |||||||
| Gentamicin | |||||||
| Kanamycin | |||||||
| Neomycin | |||||||
| Netilmicin | |||||||
| Paromomycin | |||||||
| Streptomycin | |||||||
| Tobramycin | |||||||
| Sulphamethoxazole and trimethoprim | |||||||
| Amoxicillin | |||||||
| Nalidixic acid | |||||||
| Chloramphenicol | |||||||
| Tetracycline |
Factor group: the study group in which the factor was present or applied (e.g. a group of turkeys in which chlortetracycline was administered in-feed).
Comparator group: the study group in which the factor was not present or applied (e.g. a group of turkeys in which chlortetracycline was not administered in-feed).
Birds in both the factor and comparator groups were administered antimicrobials in ovo and as poults (eggs were dipped into a solution of tylosin (300 μl/ml) and gentamicin (500 ppm), and poults received 1 mg of gentamicin via injection after hatching) [41].
The factor and comparator groups are representative of the same group of birds, sampled after and before antimicrobial administration, respectively [51].
Description of factors (biosecurity theme) potentially associated with AMR in E. coli from turkeys
| Population | Study design | Factor group | Comparator group | Bacteria | Resistance outcome | Location | Reference |
|---|---|---|---|---|---|---|---|
| Commercial turkeys | Observational | Close proximity of watercourse to poultry houses | Watercourse far from poultry houses | Combination: ampicillin, plus ceftazidime and/or cefotaxime and potentially cefoxitin or ciprofloxacin as well | Great Britain | [ | |
| Designated gloves available for farm staff | Designated gloves not available for farm staff | ||||||
| Disinfection of floors and walls at depopulation | No disinfection of floors and walls at depopulation | Ciprofloxacin | |||||
| Evidence of mice | No evidence of mice | ||||||
| Growth on litter used by chickens | Growth on un-used litter | Ceftiofur | Canada | [ | |||
| Gentamicin | |||||||
| Pigs present on neighbouring farms | Pigs not present in neighbouring farms | Combination: ampicillin, plus ceftazidime and/or cefotaxime and potentially cefoxitin or ciprofloxacin as well | Great Britain | [ | |||
| Staff work with other livestock | Staff do not work with other livestock | ||||||
| Breeder turkeys | Observational | Foot dips replenished more than once a week | Foot dips not replenished more than once a week | Ciprofloxacin | Great Britain | [ | |
| Horses present on neighbouring farms | Horses not present on neighbouring farms | ||||||
| Other domestic animals present on the farm | Domestic animals not present on the farm | Combination: ampicillin, plus ceftazidime and/or cefotaxime and potentially cefoxitin or ciprofloxacin as well | |||||
| Water sourced from main supply | Water not sourced from main supply |
No biosecurity factors potentially associated with AMR in Campylobacter species or Enterococcus species were identified.
Factor group: the study group in which the factor was present or applied (e.g. a group of turkeys in which chlortetracycline was administered in-feed).
Comparator group: the study group in which the factor was not present or applied (e.g. a group of turkeys in which chlortetracycline was not administered in-feed).
This reference reported cephalosporin resistance [50]. During bacterial isolation, media was infused with either cefotaxime, cefoxitin, ciprofloxacin or no antimicrobial. Disc diffusion was then applied as the antimicrobial susceptibility testing method, and the results of this testing were not separated based on the isolation media used. Third-generation cephalosporin resistance was defined as ‘resistant to ampicillin, plus ceftazidime and/or cefotaxime in the disc diffusion test’ [50], but cephalosporin resistance was not defined. Since this resistance outcome represents a combination of antimicrobial classes classified under categories I and II of importance to human medicine [24], it has been placed after factors for which a potential association with fluoroquinolone (category I) [24] resistance was reported.
Description of factors (management practices theme) potentially associated with AMR in Campylobacter species and E. coli from turkeys
| Population | Study design | Factor group | Comparator group | Bacteria | Resistance outcome | Location | Reference |
|---|---|---|---|---|---|---|---|
| Commercial turkeys | Observational | Age of the youngest birds in the flock is ≥105 days | Age of the youngest birds in the flock is <105 days | Ciprofloxacin | Great Britain | [ | |
| Feed sourced from a national compounder | Feed not sourced from a national compounder | ||||||
| Independent farm | Not an independent farm | Combination: ampicillin, plus ceftazidime and/or cefotaxime and potentially cefoxitin or ciprofloxacin as well | |||||
| Organic production | Conventional production | Ciprofloxacin | Germany | [ | |||
| Gentamicin | |||||||
| Streptomycin | |||||||
| Erythromycin | |||||||
| Nalidixic acid | |||||||
| Tetracycline | |||||||
| Ciprofloxacin | |||||||
| Gentamicin | |||||||
| Streptomycin | |||||||
| Erythromycin | |||||||
| Nalidixic acid | |||||||
| Tetracycline | |||||||
| Ciprofloxacin | USA | [ | |||||
| Norfloxacin | |||||||
| Gentamicin | |||||||
| Kanamycin | |||||||
| Clindamycin | |||||||
| Erythromycin | |||||||
| Ampicillin | |||||||
| Nalidixic acid | |||||||
| Tetracycline | |||||||
| Ciprofloxacin | Italy | [ | |||||
| Colistin | |||||||
| Cefotaxime | |||||||
| Ceftazidime | |||||||
| Gentamicin | |||||||
| Kanamycin | |||||||
| Streptomycin | |||||||
| Ampicillin | |||||||
| Nalidixic acid | |||||||
| Chloramphenicol | |||||||
| Florfenicol | |||||||
| Trimethoprim | |||||||
| Sulphamethoxazole | |||||||
| Tetracycline | |||||||
| Imipenem | USA | [ | |||||
| Ciprofloxacin | |||||||
| Ampicillin-sulbactam | |||||||
| Ceftriaxone | |||||||
| Amikacin | |||||||
| Gentamicin | |||||||
| Cefoxitin | |||||||
| Sulphamethoxazole and trimethoprim | |||||||
| Cefazolin | |||||||
| Ampicillin | |||||||
| Nalidixic acid | |||||||
| Tetracycline | |||||||
| Housing with partitions between flocks | Housing without partitions between flocks | Ciprofloxacin | Great Britain | [ | |||
| Combination: ampicillin, plus ceftazidime and/or cefotaxime and potentially cefoxitin or ciprofloxacin as well | |||||||
| Raised without antibiotics production | Conventional production | Imipenem | USA | [ | |||
| Ciprofloxacin | |||||||
| Ampicillin-sulbactam | |||||||
| Ceftriaxone | |||||||
| Amikacin | |||||||
| Gentamicin | |||||||
| Cefoxitin | |||||||
| Sulphamethoxazole and trimethoprim | |||||||
| Cefazolin | |||||||
| Ampicillin | |||||||
| Nalidixic acid | |||||||
| Tetracycline | |||||||
| Commercial turkeys | Non-observational | Birds moved to new pens (of an identical housing type) partway through a production cycle | Birds remained in the same pen for the entirety of the production cycle | Enrofloxacin | USA | [ | |
| Ampicillin | |||||||
| Breeder turkeys | Observational | Birds raised in the same house from placement to de-population | Birds not raised in the same house from placement to de-population | Combination: ampicillin, plus ceftazidime and/or cefotaxime and potentially cefoxitin or ciprofloxacin as well | Great Britain | [ | |
| Independent farm | Not an independent farm | ||||||
| Number of birds on the farm is >10 000 | Number of birds on the farm is <10 000 | Ciprofloxacin |
No management practice factors potentially associated with AMR in Enterococcus species were identified.
Factor group: the study group in which the factor was present or applied (e.g. a group of turkeys in which chlortetracycline was administered in-feed).
Comparator group: the study group in which the factor was not present or applied (e.g. a group of turkeys in which chlortetracycline was not administered in-feed).
This reference reported cephalosporin resistance [50]. During bacterial isolation, media was infused with either cefotaxime, cefoxitin, ciprofloxacin or no antimicrobial. Disc diffusion was then applied as the antimicrobial susceptibility testing method, and the results of this testing were not separated based on the isolation media used. Third-generation cephalosporin resistance was defined as ‘resistant to ampicillin, plus ceftazidime and/or cefotaxime in the disc diffusion test’ [50], but cephalosporin resistance was not defined. Since this resistance outcome represents a combination of antimicrobial classes classified under categories I and II of importance to human medicine [24], it has been placed after factors for which a potential association with fluoroquinolone (category I) [24] resistance was reported.